2 active not recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Refractory Marginal Zone Lymphoma: new trials by email Literature Review of Refractory Marginal Zone Lymphoma trials Research Report on Refractory Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma CD47 Antagonist ALX148, Lenalidomide, Rituximab - Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2021-10-13 | 2026-09-18 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Composite Lymphoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Lymphoid (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1)
ALX148 (1) · CT-P10 (1) · Cyclophosphamide (1) · Immunotherapy, Adoptive (1) · Lenalidomide (1) · Leukapheresis (1) · Rituximab (1) · fludarabine phosphate (1)
Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1)
United States (2)
Mazyar Shadman (1) · Paolo Strati, MD (1)